Search clinical trials for: Lumigan

Total 96 results

Allergan

Completed

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Spain, France, Belgium, Israel, United Kingdom, Poland, Italy, Czechia, Germany, Hungary
Allergan

Completed

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
AbbVie

Recruiting

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States, Japan
Wake Forest University Health Sciences

Recruiting

Improving Disease Severity

Psoriasis | Alopecia Areata | Polymorphous Light Eruption

United States
AbbVie

Completed

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
Laboratoires Thea

Completed

Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose

Primary Open Angle Glaucoma | Ocular Hypertension

France
Laboratoires Thea

Completed

Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients

Ocular Hypertension | Glaucoma

Estonia
University of Miami

Completed

Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes

Hypertrichosis

United States
Allergan

Completed

A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension (LOTUS)

Ocular Hypertension | Glaucoma, Open-Angle

China
Allergan

Completed

A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension (LOTUSDI)

Ocular Hypertension | Glaucoma, Open-Angle

China
University of California, San Francisco

Completed

Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata

Alopecia Areata

United States
Allergan

Completed

A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)

Ocular Hypertension | Glaucoma, Open-Angle

Korea, Republic of
Allergan

Completed

A Study of Bimatoprost 0.01% in the Clinical Setting (APPEAL-Taiwan)

Ocular Hypertension | Glaucoma, Primary Open Angle

Taiwan
Allergan

Completed

A Study of LUMIGAN® RC in the Clinical Setting

Ocular Hypertension | Glaucoma, Primary Open Angle

Canada
Salus University

Not yet recruiting

Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma (NTG)

Normal Tension Glaucoma

United States
Sun Pharmaceutical Industries Limited

Withdrawn

A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open Angle Glaucoma
University of California, San Diego

Completed

24-hour IOP-lowering Effect of 0.01% Bimatoprost

Ocular Hypertension | Glaucoma | Intraocular Pressure

United States
Allergan

Completed

A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Germany, Netherlands
Rabin Medical Center

Completed

Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues

Thyroid Associated Ophthalmopathies

Israel
Duke University

Completed

Study of Bimatoprost Gel on Eyelash Growth

Hypotrichosis | Madarosis

United States
Riphah International University

Completed

Post Isometric Relaxation and Mulligan Bent Leg Raise on Hamstring Tightness in High School Students

Hamstring Injury | Hamstring Tendon Injury

Pakistan
Northwestern University
Allergan

Completed

Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure

Intraocular Pressure | Nail Growth Cessation

United States
Allergan

Completed

Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

United States
Manistee Partners

Unknown

Topical Bimatoprost in the Treatment of Migraine

Migraine Disorders | Headache Disorders

United States
National Taiwan University Hospital

Unknown

Comparison of Different Drugs on Ocular Surface Disease in Glaucoma Patients: a Prospective Randomised Study

Glaucoma; Ocular Disorders (I.E. Caused by Ocular Disorders)

Taiwan
Allergan

Completed

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Canada, United States
Vissum, Instituto Oftalmológico de Alicante
AkkoLens Clinical bv

Completed

Efficacy of the AkkoLens IOL in Patients With Cataract

Cataract
Allergan

Completed

Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Open-Angle Glaucoma

Belgium
Allergan

Completed

A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons

Ocular Hypertension | Glaucoma, Primary Open Angle

Germany
VA Office of Research and Development
University of California, San Diego; NADI Inc.

Not yet recruiting

Comparing Hearing Aid Fitting Methods in Blast-exposed Veterans (SBA)

Auditory Diseases, Central

United States
Allergan

Completed

A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Glaucoma, Open-Angle

Austria
Allergan

Completed

Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence

Eyelashes

United States, Canada
Singapore National Eye Centre
Allergan

Unknown

Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study

Glaucoma, Angle-Closure

Singapore
Allergan

Completed

Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Switzerland
ForSight Vision5, Inc.

Completed

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert (OLE2)

Ocular Hypertension | Primary Open-Angle Glaucoma

United States
Allergan

Completed

Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Canada
ForSight Vision5, Inc.

Completed

An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product

Ocular Hypertension | Primary Open-Angle Glaucoma

United States
Peking Union Medical College Hospital
Beijing Bethune public welfare fund

Terminated

Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF

Uveitis | Macular Edema | Vascular Endothelial Growth Factor | Effect of Drugs

China
Amneal Pharmaceuticals, LLC
CBCC Global Inc.; Amneal EU, Limited

Not yet recruiting

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Ocular Hypertension | Open-angle Glaucoma

United States
Universitaire Ziekenhuizen KU Leuven
Allergan

Unknown

Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml (SPORTII)

Ocular Hypertension | Glaucoma

Belgium, Austria, Italy, Switzerland, United Kingdom
University of California, San Diego

Completed

The Effects of the Water Drinking Test on Intraocular Pressure

Glaucoma

United States
Summa Health System

Completed

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

Glaucoma | Application Site Pigmentation Changes

United States
LifeSprout, Inc.
Health Policy Associates

Active, not recruiting

LifeSprout Lumina™ Study in the Treatment of Nasolabial Folds

Nasolabial Fold

Belgium, Portugal, United Kingdom
Amneal Pharmaceuticals, LLC
CBCC Global Research

Recruiting

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

Ocular Hypertension | Glaucoma, Open-Angle

United States
Mankind Pharma Limited
CBCC Global Research

Completed

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma (Glaucoma)

Glaucoma, Open-Angle

United States
Allergan

Completed

Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

Ocular Hypertension | Glaucoma

United States
Alcon Research

Completed

An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®

Ocular Hypertension | Glaucoma
Alcon Research

Completed

Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)

Ocular Hypertension | Glaucoma | Open-Angle Glaucoma

3

Subscribe